Arg9 facilitates the translocation and downstream signal inhibition of an anti-HER2 single chain antibody

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Hu, Yi ^a,b   Qiao, Chunxia ^b   Lv, Ming ^b   Feng, Jiannan ^b   Yu, Ming ^b   Shen, Beifen ^b   Zhang, Qiuping ^a   Li, Yan ^b  

^a WUHAN UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

HER2; Single chain antibody; Translocation

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCENT DYE; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL; ARTICLE; CELL STRAIN 3T3; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; MOUSE; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; MICE; NIH 3T3 CELLS; PROTEIN BINDING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES;

EID: 84863098455     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-336     Document Type: Article

References (22)

1. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Science 1989 244 707 712 10.1126/science.2470152 2470152 (Pubitemid 19147683)
2. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Vogel C, Cobleigh M, Tripathy D, et al. J Clin Oncol 2002 20 719 726 10.1200/JCO.20.3.719 11821453 (Pubitemid 34111379)
3. A new human antitumor immunoreagent specific for ErbB2. De LC, Palmer DB, Piccoli R, Ritter MA, DAlessio G, Clin Cancer Res 2002 8 1710 1719 12060608 (Pubitemid 34633726)
4. Different membrane behaviour and cellular uptake of three basic arginine-rich peptides. Walrant A, Correia I, Jiao CY, Lequin O, Bent EH, Goasdoué N, Lacombe C, Chassaing G, Sagan S, Alves ID, Biochim Biophys Acta 2011 1808 382 393 10.1016/j.bbamem.2010.09.009 20920465
5. Intracellular delivery of quantum dots mediated by a histidine- and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism. Liu BR, Huang YW, Winiarz JG, Chiang HJ, Lee HJ, Biomaterials 2011 32 3520 3537 10.1016/j.biomaterials.2011.01.041 21329975
6. The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. Fei L, Ren L, Zaro JL, Shen WC, J Drug Target 2011 19 675 680 10.3109/1061186X.2010.531729 21142649
7. Happy birthday cell penetrating peptides: already 20 years. Brasseur R, Divita G, Biochim Biophys Acta 2010 1798 2177 2181 10.1016/j.bbamem.2010.09.001 20826125
8. Cell penetrating peptides: from molecular mechanisms to therapeutics. Morris MC, Deshayes S, Heitz F, Divita G, Biology of the Cell 2008 100 201 207 10.1042/BC20070116 18341479 (Pubitemid 351517084)
9. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Matjaz Z, Ulo L, Adv Drug Deliv Rev 2005 57 529 545 10.1016/j.addr.2004.10.010 15722162 (Pubitemid 40255559)
10. A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Cellina CS, Hovav N, Shira K, Nadav L, Ahuva N, Razin E, Blood 2003 102 2506 2512 10.1182/blood-2002-12-3921 12791661 (Pubitemid 37193589)
11. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB, Proc Natl Acad Sci USA 2000 97 13003 13008 10.1073/pnas.97.24.13003 11087855
12. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. He D, Yang H, Lin Q, Huang H, Int J Biochem Cell Biol 2005 37 192 205 10.1016/j.biocel.2004.06.015 15381161 (Pubitemid 39286035)
13. Construction, expression and internalization study of human anti-HBsAg single chain antibody/EGFP fusion proteins containing Arg9. Xue Q, Wen HW, Meng YL, et al. China Biotechnol 2006 26 1 6
14. Possible existence of common internalization mechanisms among arginine-rich peptides. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y, J Biol Chem 2002 277 2437 2443 10.1074/jbc.M110017200 11711547 (Pubitemid 34953265)
15. Arginine-rich peptides An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. Futaki S, Suzuki T, Ohashi W, et al. J Biol Chem 2001 276 5836 5840 10.1074/jbc.M007540200 11084031
16. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Zaro JL, Shen WC, Biochem Biophys Res Commun 2003 307 241 247 10.1016/S0006-291X(03)01167-7 12859946 (Pubitemid 36818860)
17. Mitochondria as therapeutic targets for cancer chemotherapy. Galluzzi L, Larochette N, Zamzami N, Kroemer G, Oncogene 2006 25 4812 4830 10.1038/sj.onc.1209598 16892093 (Pubitemid 44192089)
18. Guanidine-containing molecular transporters: sorbitol-based transporters show high intracellular selectivity toward mitochondria. Maiti KK, Lee WS, Takeuchi T, et al. Angew Chem Int Ed Engl 2007 46 5880 5884 10.1002/anie. 200701346 17607670 (Pubitemid 47236461)
19. Cell-permeable pepide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Zhao K, Zhao GM, Wu D, et al. J Biol Chem 2004 279 34682 34690 10.1074/jbc.M402999200 15178689 (Pubitemid 39318098)
20. Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. Horobin RW, Trapp S, Weissig V, J Control Release 2007 121 125 136 10.1016/j.jconrel.2007. 05.040 17658192 (Pubitemid 47212544)
21. Biological effects of anti-ErbB2 signal chain antibody selected for internalizing function. Richard MN, Ulri BN, Dmitri B, Marie AP, James DM, Christopher CB, Biochem Biophys Res Commun 2001 28 274 278
22. Presentation and outcome in cancer patients with extensive spread to the brain. Nieder C, Pawiniski A, Dalhaug A, BMC Res Notes 2009 2 247 10.1186/1756-0500-2-247 20003374